专利固体脂质纳米颗粒的配方优化和评估安布里森坦的肺动脉高血压的肺动脉高血压
Harshada Shewale1, Abhishek Kanugo1,2
1SVKM NMIMS School of Pharmacy and Technology Management Shirpur, Dhule, Maharashtra, India-425405; 2SVKM Institute of Pharmacy, Dhule-424001.
Recent patents on nanotechnology
|October 2, 2024
概括
固体脂质纳米颗粒 (SLN) 显著提高了口服安布里森坦的生物可用性,这是一种治疗肺动脉高血压的药物. 这种新的配方提高了药物的溶解性,并提供持续释放,提高了治疗疗效和患者的服药性.
科学领域:
- 制药科学 制药科学
- 材料科学 材料科学 材料科学
背景情况:
- 安布里森坦是一种内分泌素受体对抗剂,对于控制肺动脉高血压至关重要.
- 它的治疗用途受到溶解性差和口服生物利用率低的限制.
研究的目的:
- 使用固体脂质纳米颗粒 (SLN) 提高安布里森坦的溶解性和口服生物可用性.
- 开发一种新的口服药物输送系统,以改善高血压治疗.
主要方法:
- 固体脂质纳米颗粒 (SLN) 通过高压同质化,使用甘油单酸和Tween 80进行配制.
- 基于颗粒大小和捕获效率,Box-Behnken设计优化了SLN配方.
- 物理化学表征包括XRD,FTIR,DSC和SEM分析.
主要成果:
- 优化的SLN配方 (F1批) 的粒子大小为130nm,Z电位为-18.9mV,捕获效率为85.73%.
- 使用阿姆布里森坦的SLN在24小时内表现出双重释放 (快速和持续) 的特征.
- SEM证实了体分散的球形形态.
结论:
- SLN配方显著改善了安布里森坦的溶解性和溶解率.
- 持续的口服治疗提高了患者的舒适性,服从性和整体治疗结果.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
137
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
137
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
155
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
155
Factors Influencing Drug Absorption: Pharmaceutical Parameters
122
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
122
Factors Affecting Dissolution: Particle Size and Effective Surface Area
753
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
753
Biopharmaceutics and Pharmacokinetics: Overview
1.9K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
1.9K


